항체 의약품 : 기술 및 세계 시장

The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.

The North American market for antibody drugs is expected to grow from $132.2 billion in 2024 and is projected to reach $215.9 billion by the end of 2029, at a CAGR of 10.3% during the forecast period of 2024 to 2029.

The European market for antibody drugs is expected to grow from $71.6 billion in 2024 and is projected to reach $126.9 billion by the end of 2029, at a CAGR of 12.1% during the forecast period of 2024 to 2029.

Report Scope

This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).

BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.

Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.

The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America-the U.S., Canada and Mexico; Europe-Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific-China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.

Report Includes

• 76 data tables and 55 additional tables
• An updated review of the global market for antibody drugs
• Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
• Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
• Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
• An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
• Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
• Competitive intelligence, including companies' market shares, recent M&A activity and venture funding
• Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Insights

Chapter 2 Market Overview

• Antibodies and Antigens
• Antibody Functions
• Monoclonal Antibodies
• History of Monoclonal Antibodies
• Monoclonal Antibodies: Advantages and Disadvantages
• Types of Monoclonal Antibodies
• Manufacturing Technologies of Monoclonal Antibodies
• Applications of Monoclonal Antibodies

Chapter 3 Market Dynamics

• Drivers
• Increasing Incidence of Cancer and Autoimmune Diseases
• New Product Launches
• Restraints
• High Prices and Pricing Pressure
• Side Effects and Limitations of mAbs
• Opportunities
• Licensing and Collaboration Agreements
• Manufacturing Advances and Improving Product Yields

Chapter 4 Regulatory Aspects

• Regulatory Scenario
• Price Controls
• New Approvals of Monoclonal Antibodies

Chapter 5 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Bispecific Antibodies and Multi-Specific Antibodies
• Antibody-Drug Conjugates
• Antibody Fusion Proteins
• AI and ML in Antibody Drug Engineering

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Antibody Drugs, by Antibody Type
• Human Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Murine Monoclonal Antibodies
• Global Market for Antibody Drugs, by Manufacturing Process
• Mammalian Cell Culture
• Microbial Cell Fermentation
• Global Market for Antibody Drugs, by Application
• Market by Application
• Autoimmune Diseases
• Solid Tumors
• Lymphoma, Leukemia and Multiple Myeloma
• Others
• Geographic Breakdown
• Global Market for Antibody Drugs, by Region
• Market Size and Forecast
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 7 Competitive Intelligence

• Competitive Landscape
• Market Share for Human Monoclonal Antibodies
• Market Share for Humanized Monoclonal Antibodies
• Market Share for Chimeric Monoclonal Antibodies

Chapter 8 New Developments and Clinical Trial Activities

• New Developments and M&A Analysis
• Clinical Trial Activities
• Phase I Clinical Trials
• Phase II Clinical Trials
• Phase III Clinical Trials
• Phase IV Clinical Trials

Chapter 9 Sustainability: An ESG Perspective in the Antibody Drugs Market

• Sustainability in the Antibody Drugs Market
• Understanding the ESG Data
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 10 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI